Proteintech acquires ChromoTek
Proteintech, a German-based producer of antibodies, proteins, and immunoassays, has acquired ChromoTek, a manufacturer of camelid single-domain antibodies (aka nanobodies).
HJF to develop herpes virus vaccines
The Henry M. Jackson Foundation for the Advancement of Military Medicine (HJF) and Citranvi Biosciences have signed an exclusive licensing agreement to develop vaccine technologies to prevent cytomegalovirus and Epstein-Barr virus infections.
Aridis touts positive preclinical results for COVID-19 mAb treatment
Anti-infective therapies firm Aridis Pharmaceutical has developed an inhalable highly neutralizing monoclonal antibody (mAb) that eradicated the novel coronavirus in infected rodents.
Akron, Synairgen partner on IFN-beta treatment for COVID-19
Cell therapeutics company Akron Biotechnology and respirator drug development firm Synairgen have partnered to advance interferon-beta (IFN-beta) treatment for patients with COVID-19.
Ultimovacs touts positive early clinical results for universal cancer vaccine
Ultimovacs reported five-year overall survival data from its phase I clinical trial evaluating UV1, a universal cancer vaccine candidate, in patients with non-small cell lung cancer.
Samsung Biologics, BioEleven partner on cancer immunotherapy
Samsung Biologics has entered into a strategic partnership with BioEleven to develop and manufacture BN-101A, a third-generation immunotherapy to treat cancer.
Reaction Biology, 4HF Biotec offer new cell-based services
Reaction Biology and 4HF Biotec announced that they are offering a new cell-based service that will give customers a comprehensive understanding of their candidates. The service will combine Reaction's ProLiFiler cell assay service with 4HF's Biomarker Analysis and Mode of Action (MoA) Finder tools
OneOncology launches OneR, precision oncology research network
OneOncology has formed a subsidiary named OneOncology Research Network (OneR) as a national nonexclusive clinical trial site management organization to enhance research programs underway at participating community oncology practices.
Oncopeptides submits IND for peptide drug conjugate platform
Oncopeptides has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration for OPD5, a second drug candidate based on its proprietary peptide drug conjugate platform.
Endo to acquire BioSpecifics
Endo will acquire all shares of BioSpecifics Technologies for $88.50 per share, or an estimated total of $540 million. As part of the acquisition, BioSpecifics will receive a royalty stream from Endo's collagenase-based therapies, including Xiaflex and Qwo, which were developed by BioSpecifics.
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter